• Pneumagen reorganizes as NorthLinks Bio to develop HEX17 mCBM nasal spray for the prevention of viral respiratory infections

  University of St Andrews spin out Pneumagen has reorganized as a US-based company called NorthLinks Bio, the company said, though research will continue in Scotland. Pneumagen CEO Douglas Thomson has joined the board of the… [Read more . . .]

• MannKind gets Breakthrough T1D grant to support trial of Afrezza insulin DPI in pediatric patients

  MannKind Corporation announced that a grant from Breakthrough T1D (formerly JDRF) will be used to support the Phase 2 INHALE-1ST trial of Afrezza in children aged 10 and up with a recent Type 1 diabetes diagnosis, which was initiated earlier… [Read more . . .]

• Kither Biotech announces results from Phase 1 trial of KIT2014 inhaled PDE3/4 inhibitor for the treatment of CF

  Turin, Italy -based Kither Biotech says that a Phase 1 clinical study of its KIT2014 inhaled PDE3/4 inhibitor successfully demonstrated that the nebulized formulation was safe and well tolerated, with very limited systemic exposure. The… [Read more . . .]

• SpliSense gets up to $13 million in additional funding from the CFF

  SpliSense announced that it has secured up to $13 million in new funding from the Cystic Fibrosis Foundation to support an ongoing Phase 2 trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic… [Read more . . .]

• Iconovo signs strategic collaboration agreement with Lonza

  According to DPI developer Iconovo, the company has now signed a strategic collaboration deal with CDMO Lonza for development of spray dried formulation of inhaled biologics. In January 2025, Iconovo said that Lonza would develop spray dried… [Read more . . .]

• FDA approves Rx to OTC switch for Amphastar’s Rextovy naloxone nasal spray

• UK approves 1 mg dose of ALK’s EURneffy adrenaline nasal spray for children aged 4 and up

• RDD 2026 in review

• Lupin partners with ERN for launch Luforbec beclometasone / formoterol MDI in Spain

• MannKind initiates Phase 2 INFLO-2 trial of MNKD-201 nintedanib DPI in patients with IPF

More news . . .